Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 21148524.
- Also identified by DOI 10.1093/cid/ciq002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For these circumstances, we propose some modifications to existing treatment guidelines for BCG infection.
Medical subject headings
- Bacteremia
- Biological Therapy
- Drug Resistance, Bacterial
- Immunotherapy
- Isoniazid
- Mycobacterium bovis
- Urinary Bladder Neoplasms